Reboxetine: the first selective noradrenaline re-uptake inhibitor.
about
Dopamine physiology in the basal ganglia of male zebra finches during social stimulation.Estimation of binding rate constants using a simultaneous mixed-effects method: application to monoamine transporter reuptake inhibitor reboxetineThe cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine.Noradrenaline and Parkinson's disease.Reboxetine: a preliminary report on its use through the Special Access ProgramLinking the evidence between urinary retention and antipsychotic or antidepressant drugs: A systematic review.Drug treatment of depression in the 2000s: An overview of achievements in the last 10 years and future possibilities.3-Aryl-3-arylmethoxyazetidines. A new class of high affinity ligands for monoamine transporters.Synthesis and monoamine transporter affinity of 3alpha-arylmethoxy-3beta-arylnortropanes.Effectiveness of reboxetine in treatment of outpatient children and adolescents with attention deficit-hyperactivity disorder with comorbid anxiety disorders.Acute and Chronic Noradrenergic Effects on Cortical Excitability in Healthy Humans.Reboxetine in therapy-resistant enuresis: a retrospective evaluation.Norepinephrine but not serotonin reuptake inhibitors enhance theta and gamma activity of the septo-hippocampal system.Acute and chronic effects of noradrenergic enhancement on transcranial direct current stimulation-induced neuroplasticity in humans.
P2860
Q28610467-82F34EBA-1891-4974-BF7B-C2E1F1A95CCBQ33870452-369C50CF-E46B-44A6-A095-04A0D75BE892Q34496400-4D7DAD0B-A282-4313-92BF-92DBD8A04A4EQ35013240-AE2911DE-B373-43D5-8562-10AC0EA1ED65Q35101103-9335EBDC-E156-4F76-9DC2-6831CFE20483Q35750383-88EC5296-3492-45CE-B308-A8926BE12E7AQ36637666-E62722B8-8F59-454F-BB76-0F947A67217AQ37071547-B22C122A-027F-434E-8F2F-0683A0AFA2F7Q37460264-F12F1D2C-ED60-4EDD-BE0E-71B8EA69C579Q41515634-1C0C9641-ABA5-46C2-8F2A-CF5629FFD007Q41545918-313597A1-FD41-450F-AF87-B3B8066EF3E2Q43239651-4C8B06C6-A7B2-488A-8F79-9F1027CE51EFQ44362506-FF98A40D-93D8-4CE9-8701-4B4B16B8BCADQ48019262-15993919-6CE7-421D-8DE7-47964CBFE6A3
P2860
Reboxetine: the first selective noradrenaline re-uptake inhibitor.
description
2000 nî lūn-bûn
@nan
2000 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Reboxetine: the first selective noradrenaline re-uptake inhibitor.
@ast
Reboxetine: the first selective noradrenaline re-uptake inhibitor.
@en
Reboxetine: the first selective noradrenaline re-uptake inhibitor.
@nl
type
label
Reboxetine: the first selective noradrenaline re-uptake inhibitor.
@ast
Reboxetine: the first selective noradrenaline re-uptake inhibitor.
@en
Reboxetine: the first selective noradrenaline re-uptake inhibitor.
@nl
prefLabel
Reboxetine: the first selective noradrenaline re-uptake inhibitor.
@ast
Reboxetine: the first selective noradrenaline re-uptake inhibitor.
@en
Reboxetine: the first selective noradrenaline re-uptake inhibitor.
@nl
P2093
P356
P1476
Reboxetine: the first selective noradrenaline re-uptake inhibitor.
@en
P2093
P2860
P304
P356
10.1517/14656566.1.4.771
P407
P577
2000-05-01T00:00:00Z